New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
09:19 EDTVRX, AGNValeant's raised Allergan bid may not be enough, says Wells Fargo
Wells Fargo believes Valeant's (VRX) new offer for Allergan (AGN), which includes $10 more per share in cash and a $25 per share contingent value right for DARPin, may still be insufficient for Allergan. Wells notes that based on Valeant's last closing price, the total new offer for Allergan is around $166 per share. Shares of Allergan are down $1.03 to $163.99 in pre-market trading while Valeant shares are down 99c to $128.96.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use